UCL Mont-Godinne
- Address
- Avenue Dr-Gaston-Therasse 1, 5530 Yvoir, Belgium
Cardiovascular Disease Research
At UCL Mont-Godinne, clinical research in cardiology focuses on cardiovascular diseases, especially coronary artery disease. The trials are designed to assess whether new approaches can better prevent major heart and vascular events and improve long-term outcomes for patients.
- Prevention of heart attack, stroke, and repeat coronary procedures in patients with coronary artery disease
- Evaluating treatment effectiveness after percutaneous coronary intervention
- Studying ways to reduce serious cardiovascular complications
This work reflects a strong interest in improving everyday care for people with established heart disease through better event prevention and outcome measurement.
Oncology Trials in Solid Tumors
The site is also active in neoplasm research, with studies involving non-small cell lung cancer, metastatic melanoma, and squamous cell carcinoma of the head and neck. These trials explore new treatment options for patients with advanced cancers and aim to improve survival and disease control.
- Testing new therapies for advanced solid tumors
- Comparing outcomes such as progression-free survival and overall survival
- Supporting better treatment selection for hard-to-treat cancers
Research at UCL Mont-Godinne in this area centers on expanding options for patients whose cancers are newly diagnosed, locally advanced, or metastatic.
Hematologic Malignancy Studies
Another major focus is blood cancer research, particularly diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma. The clinical trials aim to improve treatment effectiveness for patients with relapsed, refractory, or newly treated disease.
- Investigating combination treatment strategies for lymphoma
- Measuring survival and disease response in aggressive hematologic cancers
- Exploring better options for patients with limited standard treatments
This research supports efforts to find more effective therapies for challenging lymphoma subtypes and to strengthen outcomes in oncology care.
Respiratory and Circulatory Physiology Research
The trial portfolio also includes work in respiratory tract diseases and circulatory and respiratory physiological phenomena, linking lung and heart-related research. Studies in this area examine how treatments may influence disease progression and broader physiological outcomes in patients with advanced respiratory illness.
- Research in advanced lung cancer and related respiratory disease settings
- Assessing treatment impact on disease control and survival
- Connecting clinical outcomes with heart-lung function and patient health
This mix of studies shows an interest in understanding both disease-specific results and the wider effects of therapy on cardiopulmonary health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 87 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 81 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1AstraZeneca AB1active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in UCL Mont-Godinne
lock Showing 1 of 26 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Janssen Cilag International | Phase II | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 87 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lenalidomide | 4 | Unknown | 2020-12-22 | 2024-09-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.